Regeneron Starts Phase 3 Trial of COVID Antibody Drug That M
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
The biotechnology company Regeneron announced the late-stage clinical trials of REGN-COV2, its investigational double-antibody cocktail for the treatment and prevention of Covid-19.

• Specifically, the release noted that a Phase 3 trial of the drug will assess its ability to prevent coronavirus infection among uninfected people who have had close contact to an infected person, such as a patient's housemate.

• The Phase 3 prevention trial is happening at around 100 sites and expected to include 2,000 patients across the United States, according to Regeneron.

• The drug also has moved into the Phase 2/3 portion of two trials testing its ability to treat hospitalized and non-hospitalized patients with Covid-19, according to Regeneron.

• These trials will involve 1,850 hospitalized patients and 1,050 non-hospitalized patients, and they are expected to be conducted at 150 sites in the United States, Brazil, Mexico and Chile.

Source: https://edition.cnn.com/2020/07/06/health/regeneron-coronavirus-antibody-drug-bn/index.html
Dr. T●●●●z H●●●●●●i and 1 others like this4 shares
Like
Comment
Share